Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Wilsons Rapid Insights Conference 2018
22 slides from Telix Pharmaceuticals's conference presentation, May 31, 2018
Slide 1: Telix Pharmaceuticals Limited (ASX:TLX) Rapid Insights Conference
For personal use only Telix Pharmaceuticals Limited (ASX:TLX) Rapid Insights Conference May, 2018
Slide 2: Notices
Notices For personal use only The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction. No representation or warranty, express or implied, is made
Slide 3: Company overview
Company overview For personal use only • Founded November 2015 • Melbourne-based with team in Europe, US and Japan • IPO, listed on the ASX in November 2017 • Raised a total of AUD $58.5m (Seed + IPO) • Fully funded for 24 months • Mission : to become a leading oncology company in the field of “mole
Slide 4: Market metrics
Market metrics $0.68 For personal use only (25th of May) Mkt. Cap. A$135m Disease Focus Oncology Clinical Stage Phase I - III Shares on Issue 197,437,500 Options on Issue 6,624,000 Cash on Hand AUD ~$45m Symbol TLX • November ‘17 IPO at $0.65 • Major investors : Fidelity, Acorn Capital, Viburnum, UV
Slide 5: Our business: Molecularly-Targeted Radiation (MTR)
Our business : Molecularly-Targeted Radiation (MTR) MTR works by chemically For personal use only attaching radioactive isotopes to targeting molecules that are very specific for cancer cells. At low doses, this enables the location of the cancer cells to be pinpointed using PET imaging. At high dos
Slide 6: Positron Emission Tomography – PET: See it, treat it
Positron Emission Tomography – “PET” See it, treat it… For personal use only • Telix develops drugs that deliver targeted radiation directly to cancer. At low doses, the patient can be imaged: TLX591 (Prostate) TLX250 (Kidney) TXL-101 (Brain) • At high doses, the patient is treated 6
Slide 7: How does Telix fit into cancer care?
How does Telix fit into cancer care? For personal use only CANCER CARE TARGETED DRUGS CHEMOTHERAPY IMMNOTHERAPY RADIOTHERAPY SURGERY Ancient times - 1890’s - 1940’s - 1990’s - 1990’s - present present present present present 7
Slide 8: Telix is modernising 1950's radiation oncology
Telix is modernising 1950’s radiation oncology Advanced image guidance and treatment planning has For personal use only improved performance but radiation oncology is still fundamentally 1950s technology Stanford University, 1950s Clinac® IX by Varian Medical Systems 8
Slide 9: A new weapon in the fight against cancer
A new weapon in the fight against cancer … For personal use only External Beam Therapy (EBT) • An fundamental part of cancer treatment Existing External • “Externally Targeted” from a machine (a linear accelerator) • ~Multi-$Bn global market. Decent procedure growth, but linear accelerator growth is
Slide 10: Pipeline development over the next months
Pipeline development over the next 24 months For personal use only Isotope Target Agent Phase I Phase II Phase III Commercial Therapy Kidney 177Lu CA-IX Antibody TLX250 (Girentuximab) 89Zr CA-IX Antibody TLX250-Cdx (Girentuximab) Imaging Prostate 177Lu PSMA Antibody TLX591 Therapy 68Ga Small Imaging
Slide 11: Substantial clinical evidence
Substantial clinical evidence Under compassionate use in For personal use only Germany, glioblastoma patients treated with TLX101 have lived 170 metastatic 30 or 40 months instead of 6 prostate cancer months patients have demonstrated a 30+ month survival benefit 40 patients with advanced, progressi
Slide 12: Market opportunity
Market opportunity All of TLX’s current valuation For personal use only Therapy Imaging is here… • Potential to treat 50,000 patients (US/EU5) • TLX250 imaging is a $200m revenue opportunity in TLX250 • Follow-on therapy to immunotherapy its own right. We expect to complete Phase III • May enhance e
Slide 13: Current program status
Current program status For personal use only TLX250 (renal cancer) • Imaging : Phase III bridging study – first patient in any day. Phase III imaging IMPD (Europe) filed late June / early July • Therapy : Phase II study (US) IND in preparation TLX591 (prostate cancer) • Imaging : Drug Master File in
Slide 14: A major inflection in Q3: getting to first revenues
A major inflection in Q3 : getting to first revenues… For personal use only What is an Imaging “Kit”? Injectable Kit The end product is a Generator syringe of radiolabelled imaging agent that is ready to inject into the patient. An hour after injection, the patient is 68Ga is produced from a Kit : A
Slide 15: Watchful waiting means a big commercial opportunity for prostate imaging
A lot of watchful For personal use only waiting means a big commercial opportunity for prostate imaging 15
Slide 16: Imaging matters … and PSMA imaging is very sensitive
Salivary and D lacrimal gland Imaging matters … and PSMA imaging is very sensitive uptake is normal For personal use only A B C It is possible to image disease with PSMA-11, even at very low PSA levels High Slight liver kidney (= low tumour burden). uptake uptake The three panels A)-C) illustrate ho
Slide 17: And can potentially transform therapy
And can potentially transform therapy… (castration isn’t nice) For personal use only Before After 17
Slide 18: A potential game-changer in the management of prostate cancer
A potential game-changer in the management of prostate cancer… PSMA For personal use only Expression Our opportunity is to induce androgen deprivation for a short Androgen time (short-term hormone use) to drive PSMA expression and then Deprivation WHAM … hit cancer that has been sensitised to PSMA t
Slide 19: Management team
Dr. Michael Wheatcroft (Director of R&D) After completing a PhD in the Department of Biochemistry, Cambridge University, Mike worked at Management team Cambridge Antibody Technology (now Medimmune). After moving to Melbourne in 2010, Mike oversaw the pre-clinical development of several engineered an
Slide 20: Board of Directors
Board of Directors For personal use only Mr H. Kevin McCann AM (Chairman) Mr. Oliver Buck Kevin is currently Chairman of Citadel Group and Dixon Hospitality Non-executive Director Limited. He is a former Chairman of Macquarie Bank Limited, Origin Oliver is Founder of ITM Group, one of the largest is
Slide 21: International scientific advisory board
International scientific advisory board For personal use only Dr. Rodney Hicks Dr. Neil Bander Chair of Urology at Weill Cornell Medical Centre (NY, USA). First led the development of Chief of Nuclear Medicine and Radiology, Peter MacCallum Cancer Centre PSMA-targeting radiopharmaceuticals for prost
Slide 22: Upcoming catalysts
Upcoming catalysts For personal use only • In progress : completion of the acquisition of Atlab SAS • June/July : completion of FDA review of the manufacturing package for prostate imaging program • Commencement of commercial activity for prostate program – Q3 first revenues • June : formal launch o
Telix Pharmaceuticals — Wilsons Rapid Insights Conference 2018 on 6ix